Progress on the hepatotoxicity of lipid-lowering drugs and its prevention strategies

XU Yancheng; FANG Yijie; YAN Lan; JIANG Yuanying; CAO Yongbing

doi:10.3969/j.issn.1006-0111.2014.06.004

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 32 Issue 6

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2014 > 32(6): 412-415,464

XU Yancheng, FANG Yijie, YAN Lan, JIANG Yuanying, CAO Yongbing. Progress on the hepatotoxicity of lipid-lowering drugs and its prevention strategies[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 412-415,464. doi: 10.3969/j.issn.1006-0111.2014.06.004

Citation:

XU Yancheng, FANG Yijie, YAN Lan, JIANG Yuanying, CAO Yongbing. Progress on the hepatotoxicity of lipid-lowering drugs and its prevention strategies[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 412-415,464. doi: 10.3969/j.issn.1006-0111.2014.06.004

Progress on the hepatotoxicity of lipid-lowering drugs and its prevention strategies

doi: 10.3969/j.issn.1006-0111.2014.06.004

1.
School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China;School of Pharmacy, Second Military Medical University, Shanghai 200433, China
2.
School of Pharmacy, Second Military Medical University, Shanghai 200433, China;School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang 110016, China
3.
School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2013-10-29
Rev Recd Date: 2014-06-11

Abstract

Hepatotoxicity is one of the most common adverse reactions during anti-hyperlipidemia treatment. Mechanisms of anti-hyperlipidemia drug-induced hepatotoxicity are not clear yet, but most of the toxic reactions are dose-related hypersensitivity and could be released after drug withdrawal. It is accepted that clinical risk factors for the development of hepatotoxicity during anti-hyperlipidemia treatment are high age and chronic illnesses. Treatment of anti-hyperlipidemia drug-induced hepatotoxicity has not been unified and most of the treatments are non-specific and symptomatic. Researching hypotoxicity and hepatoprotection antihyperlipidemia drug, especially TCM and pharmaceutics will become a promising direction.
- hyperlipidemia,
- drug,
- hepatotoxicity

References

[1]	Grundy SM, Cleeman JI, Merz CN,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines[J]. J Am Coll Cardiol,2004,44(3):720-732.
[2]	Argo CK, Loria P, Caldwell SH, et al. Statins in liver disease: a molehill, an iceberg, or neither?[J]. Hepatology, 2008,48(2):662-669.
[3]	Talbert RL. Safety issues with statin therapy[J]. J Am Pharm Assoc,2006;46(4):479-488.
[4]	Vuppalanchi R, Chalasani N. Statins for hyperlipidemia in patients with chronic liver disease: are they safe?[J]. Clin Gastroenterol Hepatol,2006,4(7):838-839.
[5]	李光明, 范建高. 慢性肝病患者应用他汀的安全性及疗效[J]. 中华肝脏病杂志,2010,18(5):328-330.
[6]	Cash J, Callender ME, McDougall NI, et al. Statin safety and chronic liver disease[J]. Int J Clin Pract,2008,62(12): 1831-1835.
[7]	Gupta NK, Lewis JH. Review article: the use of potentially hepatotoxic drugs in patients with liver disease[J]. Aliment Pharmacol Ther,2008,28(9): 1021-1041.
[8]	Jimenez-Alonso J, Osorio JM, Guierrez-Cabello F, et al. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus[J]. A Arch Intern Med,1999,159(15):1811-1812.
[9]	de Castro ML, Hermo JA, Baz A, et al. Acute cholestatic hepatitis afteratorvastatin reintroduction[J]. Gastroenterol Hepatol,2006,29(1):21-24.
[10]	Nakad A, Bataille L, Hamoir V, et al. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin[J]. Lancet,1999,353(9166):1763-1764.
[11]	Gershovich OE, Lyman AE. Liver function test abnormalities and pruritis in a patient treated with atorvastatin: case report and review of the literature[J]. Pharmacotherapy,2004,24(1):150-154.
[12]	Grimbert S, Pessayre D, Degott C, et al. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin[J]. Dig Dis Sci,1994,39(9):2032-2033.
[13]	Vuppalanchi R, Teal E. Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes[J]. Am J Med Sci,2005,329(2):62-65.
[14]	Ricaurte B, Guirguis A, Taylor HC, et al. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity[J]. Ann Pharmacother,2006,40(4):753-757.
[15]	Kanathur N, Mathai MG, Byrd RP Jr, et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis[J]. Tenn Med,2001,94(9):339-341.
[16]	Caldwell SH, Hespenheide EE, von Borstel RW. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin[J]. Dig Dis Sci,2001,46(2):376-378.
[17]	Ashar U, Desai D, Bhaduri A. Flutamide-induced hepatotoxicity with possible potentiation by simvastatin[J]. J Assoc Physicians India,2003,51(1):75-77.
[18]	Cornwell PD, De Souza AT, Ulrich RG. Profiling of hepatic gene expression in rats treated with fibric acid analogs[J]. Mutat Res,2004,549(12):131-145.
[19]	Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates[J]. Am J Cardiol,2004,94(7):935-938.
[20]	Grubisic-Cabo F, Vrdoljak E. Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy[J]. Med Oncol,2006,23(1):121-124.
[21]	Vogt A, Kassner U, Hostalek U, et al. NAUTILUS Study Group. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study[J]. Curr Med Res Opin,2006,22(2):417-425.
[22]	Henkin Y, Johnson KC, Segrest JP. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin[J]. JAMA,1990,264(2):241-243.
[23]	Moon YS, Kashyap ML. Niacin extended-release/lovastatin: combination therapy for lipid disorders[J]. Expert Opin Pharmacother,2002,3(12):1763-1771.
[24]	Coppola A, Brady PG, Nord HJ. Niacin-induced hepatotoxicity: unusual presentations[J]. South Med J,1994,87(1):30-32.
[25]	McKenney J. Niacin for dyslipidemia: considerations in product selection[J]. Am J Health Syst Pharm,2003,60(10):995-1005.
[26]	Stolk MF, Becx MC, Kuypers KC, et al. Severe hepatic side effects of ezetimibe[J]. Clin Gastroenterol Hepatol,2006,4(7):908-911.
[27]	Cruz-Fernandez JM, Bedarida GV, Adgey J, et al. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease[J]. Int J Clin Pract,2005,59(6):619-627.
[28]	Armani A, Toth PP. Colesevelam hydrochloride in the management of dyslipidemia[J]. Expert Rev Cardiovasc Ther,2006,4(3):283-291.
[29]	Sirmans SM, Beck JK, Banh HL, et al. Colestipol-induced hepatotoxicity[J]. Pharmacotherapy,2001,21(4):513-516.
[30]	Graf D, Kohlmann C, Haselow K, et al. Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and independent pathways in rat liver[J]. Hepatology,2006,44(5):1206-1217.
[31]	Brewer HB Jr. High-density lipoprotein: a new potential therapeutic target for the prevention of cardiovascular disease[J]. Arterioscler Thromb Vasc Biol,2004,24:387-391.
[32]	FDA Statement: Pfizer Stops All Torcetrapib Clinical Trials in Interest of Patient Safety[R].2006.
[33]	彭颂兴, 黎玉容. 药物性肝损伤的病因与临床分析[J]. 临床医药实践,2012,21(8):586-587.
[34]	Kar kiner A,Temir G,Utku M,et al.The efficacy of nonoperative management in childhood blunt hepatic trauma[J]. Ulus Travma Derg,2005,11(2):128-133.
[35]	王慧铭, 夏道宗, 夏明,等. 香菇多糖降血脂作用及其机制的研究[J]. 浙江中西医结合杂志,2005,15(10):599-602.
[36]	狄建彬,顾振纶,赵笑东,等. 姜黄素防治大鼠高脂性脂肪肝的研究[J]. 中草药,2010,41(8):1322-1326.
[37]	段玉梅,单松波. 降血脂药物开发应用新进展[J]. 黑龙江医药,2004,17(6):449-451.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(2772) PDF downloads(238) Cited by()

Proportional views

Progress on the hepatotoxicity of lipid-lowering drugs and its prevention strategies

1. School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China;School of Pharmacy, Second Military Medical University, Shanghai 200433, China

2. School of Pharmacy, Second Military Medical University, Shanghai 200433, China;School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang 110016, China

3. School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2013-10-29

Rev Recd Date: 2014-06-11

Key words:

hyperlipidemia /
drug /
hepatotoxicity

Abstract: Hepatotoxicity is one of the most common adverse reactions during anti-hyperlipidemia treatment. Mechanisms of anti-hyperlipidemia drug-induced hepatotoxicity are not clear yet, but most of the toxic reactions are dose-related hypersensitivity and could be released after drug withdrawal. It is accepted that clinical risk factors for the development of hepatotoxicity during anti-hyperlipidemia treatment are high age and chronic illnesses. Treatment of anti-hyperlipidemia drug-induced hepatotoxicity has not been unified and most of the treatments are non-specific and symptomatic. Researching hypotoxicity and hepatoprotection antihyperlipidemia drug, especially TCM and pharmaceutics will become a promising direction.

HTML

Reference (37)

[1]	Grundy SM, Cleeman JI, Merz CN,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines[J]. J Am Coll Cardiol,2004,44(3):720-732.
[2]	Argo CK, Loria P, Caldwell SH, et al. Statins in liver disease: a molehill, an iceberg, or neither?[J]. Hepatology, 2008,48(2):662-669.
[3]	Talbert RL. Safety issues with statin therapy[J]. J Am Pharm Assoc,2006;46(4):479-488.
[4]	Vuppalanchi R, Chalasani N. Statins for hyperlipidemia in patients with chronic liver disease: are they safe?[J]. Clin Gastroenterol Hepatol,2006,4(7):838-839.
[5]	李光明, 范建高. 慢性肝病患者应用他汀的安全性及疗效[J]. 中华肝脏病杂志,2010,18(5):328-330.
[6]	Cash J, Callender ME, McDougall NI, et al. Statin safety and chronic liver disease[J]. Int J Clin Pract,2008,62(12): 1831-1835.
[7]	Gupta NK, Lewis JH. Review article: the use of potentially hepatotoxic drugs in patients with liver disease[J]. Aliment Pharmacol Ther,2008,28(9): 1021-1041.
[8]	Jimenez-Alonso J, Osorio JM, Guierrez-Cabello F, et al. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus[J]. A Arch Intern Med,1999,159(15):1811-1812.
[9]	de Castro ML, Hermo JA, Baz A, et al. Acute cholestatic hepatitis afteratorvastatin reintroduction[J]. Gastroenterol Hepatol,2006,29(1):21-24.
[10]	Nakad A, Bataille L, Hamoir V, et al. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin[J]. Lancet,1999,353(9166):1763-1764.
[11]	Gershovich OE, Lyman AE. Liver function test abnormalities and pruritis in a patient treated with atorvastatin: case report and review of the literature[J]. Pharmacotherapy,2004,24(1):150-154.
[12]	Grimbert S, Pessayre D, Degott C, et al. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin[J]. Dig Dis Sci,1994,39(9):2032-2033.
[13]	Vuppalanchi R, Teal E. Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes[J]. Am J Med Sci,2005,329(2):62-65.
[14]	Ricaurte B, Guirguis A, Taylor HC, et al. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity[J]. Ann Pharmacother,2006,40(4):753-757.
[15]	Kanathur N, Mathai MG, Byrd RP Jr, et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis[J]. Tenn Med,2001,94(9):339-341.
[16]	Caldwell SH, Hespenheide EE, von Borstel RW. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin[J]. Dig Dis Sci,2001,46(2):376-378.
[17]	Ashar U, Desai D, Bhaduri A. Flutamide-induced hepatotoxicity with possible potentiation by simvastatin[J]. J Assoc Physicians India,2003,51(1):75-77.
[18]	Cornwell PD, De Souza AT, Ulrich RG. Profiling of hepatic gene expression in rats treated with fibric acid analogs[J]. Mutat Res,2004,549(12):131-145.
[19]	Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates[J]. Am J Cardiol,2004,94(7):935-938.
[20]	Grubisic-Cabo F, Vrdoljak E. Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy[J]. Med Oncol,2006,23(1):121-124.
[21]	Vogt A, Kassner U, Hostalek U, et al. NAUTILUS Study Group. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study[J]. Curr Med Res Opin,2006,22(2):417-425.
[22]	Henkin Y, Johnson KC, Segrest JP. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin[J]. JAMA,1990,264(2):241-243.
[23]	Moon YS, Kashyap ML. Niacin extended-release/lovastatin: combination therapy for lipid disorders[J]. Expert Opin Pharmacother,2002,3(12):1763-1771.
[24]	Coppola A, Brady PG, Nord HJ. Niacin-induced hepatotoxicity: unusual presentations[J]. South Med J,1994,87(1):30-32.
[25]	McKenney J. Niacin for dyslipidemia: considerations in product selection[J]. Am J Health Syst Pharm,2003,60(10):995-1005.
[26]	Stolk MF, Becx MC, Kuypers KC, et al. Severe hepatic side effects of ezetimibe[J]. Clin Gastroenterol Hepatol,2006,4(7):908-911.
[27]	Cruz-Fernandez JM, Bedarida GV, Adgey J, et al. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease[J]. Int J Clin Pract,2005,59(6):619-627.
[28]	Armani A, Toth PP. Colesevelam hydrochloride in the management of dyslipidemia[J]. Expert Rev Cardiovasc Ther,2006,4(3):283-291.
[29]	Sirmans SM, Beck JK, Banh HL, et al. Colestipol-induced hepatotoxicity[J]. Pharmacotherapy,2001,21(4):513-516.
[30]	Graf D, Kohlmann C, Haselow K, et al. Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and independent pathways in rat liver[J]. Hepatology,2006,44(5):1206-1217.
[31]	Brewer HB Jr. High-density lipoprotein: a new potential therapeutic target for the prevention of cardiovascular disease[J]. Arterioscler Thromb Vasc Biol,2004,24:387-391.
[32]	FDA Statement: Pfizer Stops All Torcetrapib Clinical Trials in Interest of Patient Safety[R].2006.
[33]	彭颂兴, 黎玉容. 药物性肝损伤的病因与临床分析[J]. 临床医药实践,2012,21(8):586-587.
[34]	Kar kiner A,Temir G,Utku M,et al.The efficacy of nonoperative management in childhood blunt hepatic trauma[J]. Ulus Travma Derg,2005,11(2):128-133.
[35]	王慧铭, 夏道宗, 夏明,等. 香菇多糖降血脂作用及其机制的研究[J]. 浙江中西医结合杂志,2005,15(10):599-602.
[36]	狄建彬,顾振纶,赵笑东,等. 姜黄素防治大鼠高脂性脂肪肝的研究[J]. 中草药,2010,41(8):1322-1326.
[37]	段玉梅,单松波. 降血脂药物开发应用新进展[J]. 黑龙江医药,2004,17(6):449-451.

Message Board

Progress on the hepatotoxicity of lipid-lowering drugs and its prevention strategies

doi: 10.3969/j.issn.1006-0111.2014.06.004

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views